Acute Myeloid Leukemia

Today's approval of Tibsovo, along with the diagnostic tool to determine who should get it, brings a new type of treatment for patients with acute myeloid leukemia.

While there are known risk factors of developing acute myeloid leukemia (AML) – such as a myelodysplastic syndrome diagnosis and receiving chemotherapy and radiotherapy – a diagnosis can still stun and individual. But researchers at Weill Cornell Medicine and New York-Presbyterian recently discovered a genomic pre-malignant biomarker of the disease that can identify people who are at a greater risk for AML.

The Food and Drug Administration (FDA) has granted a priority review to a new drug application (NDA) for glasdegib to treat patients with previously untreated acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC), which is a type of chemotherapy, according to Pfizer, the manufacturer of the drug.

The Food and Drug Administration (FDA) has granted a priority review to a new drug application (NDA) for gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia (AML), according to Astellas Pharma, the manufacturer of the FLT3 inhibitor.

“A life is not important except in the impact it has on other lives.”

As suspected, the average early mortality rate improved overall during the study period. But while evaluating the data, researchers noticed something interesting about the difference in early mortality at the NCI-designated cancer centers compared to non-NCI-designated cancer centers.

New drugs bring advancements to acute myeloid leukemia after 40 years.

Ivosidenib (AG-120) was granted a priority review designation by the Food and Drug Administration (FDA) for the treatment of patients with relapsed/refractory IDH1-mutant acute myeloid leukemia (AML), according to a statement from Agios Pharmaceuticals, the company developing the targeted therapy.

Older patients with acute myeloid leukemia (AML) often face a difficult choice: risky, intensive chemotherapy that offers a small chance of a cure versus non-intensive chemotherapy meant to improve physical comfort and quality of life.

The Food and Drug Administration has approved Rydapt (midostaurin) for acute myeloid leukemia (AML).

By donating stem cells through Be The Match, healthy adults can save the lives of people with blood cancers.

Researchers at UAB found that patients aged younger than 65 who were unmarried, lived in lower-income areas, and who were uninsured or Medicaid beneficiaries were at significantly higher risk of premature mortality.

For some, working after cancer means switching careers to pursue a passion.

A navigator-designed, proactive, weekly, telephone support call to help patients with blood cancers manage their symptoms between appointments was able to significantly reduce unplanned hospitalizations at a Colorado cancer center.

The Food and Drug Administration granted a Fast Track Designation to CPX-351 for the treatment of elderly patients with relapsed acute myeloid leukemia (AML).

In a first-in-human study, the drug AG-221 generated long-lasting remissions in patients with acute myeloid leukemia (AML).

Updates from the annual meeting of the American Society of Hematology.

Liposomal anthracycline may allow for higher dosing with less cardiotoxicity in childhood AML patients.

The latest in cancer prevention, diagnosis & treatment.

When considering a stem cell transplantation, patients with cancer must be willing to take a chance.

Minimizing and preventing late effects of stem cell transplantation.

A drug removed from the market last year to treat acute myeloid leukemia may have a second life.

Research updates from the annual San Antonio Breast Cancer Symposium and American Society of Hematology.

Adolescents with AML tend to do better with stem cell transplant.